» Articles » PMID: 38801906

Evaluation of 14 PFAS for Permeability and Organic Anion Transporter Interactions: Implications for Renal Clearance in Humans

Overview
Journal Chemosphere
Date 2024 May 27
PMID 38801906
Authors
Affiliations
Soon will be listed here.
Abstract

Per- and polyfluoroalkyl substances (PFAS) encompass a diverse group of synthetic fluorinated chemicals known to elicit adverse health effects in animals and humans. However, only a few studies investigated the mechanisms underlying clearance of PFAS. Herein, the relevance of human renal transporters and permeability to clearance and bioaccumulation for 14 PFAS containing three to eleven perfluorinated carbon atoms (η = 3-11) and several functional head-groups was investigated. Apparent permeabilities and interactions with human transporters were measured using in vitro cell-based assays, including the MDCK-LE cell line, and HEK293 stable transfected cell lines expressing organic anion transporter (OAT) 1-4 and organic cation transporter (OCT) 2. The results generated align with the Extended Clearance Classification System (ECCS), affirming that permeability, molecular weight, and ionization serve as robust predictors of clearance and renal transporter engagement. Notably, PFAS with low permeability (ECCS 3A and 3B) exhibited substantial substrate activity for OAT1 and OAT3, indicative of active renal secretion. Furthermore, we highlight the potential contribution of OAT4-mediated reabsorption to the renal clearance of PFAS with short η, such as perfluorohexane sulfonate (PFHxS). Our data advance our mechanistic understanding of renal clearance of PFAS in humans, provide useful input parameters for toxicokinetic models, and have broad implications for toxicological evaluation and regulatory considerations.

Citing Articles

In Vitro Hepatic Clearance Evaluations of Per- and Polyfluoroalkyl Substances (PFAS) across Multiple Structural Categories.

Crizer D, Rice J, Smeltz M, Lavrich K, Ravindra K, Wambaugh J Toxics. 2024; 12(9).

PMID: 39330600 PMC: 11435625. DOI: 10.3390/toxics12090672.

References
1.
Launay-Vacher V, Izzedine H, Karie S, Hulot J, Baumelou A, Deray G . Renal tubular drug transporters. Nephron Physiol. 2006; 103(3):p97-106. DOI: 10.1159/000092212. View

2.
Giacomini K, Huang S, Tweedie D, Benet L, Brouwer K, Chu X . Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9(3):215-36. PMC: 3326076. DOI: 10.1038/nrd3028. View

3.
Ducatman A, Luster M, Fletcher T . Perfluoroalkyl substance excretion: Effects of organic anion-inhibiting and resin-binding drugs in a community setting. Environ Toxicol Pharmacol. 2021; 85:103650. DOI: 10.1016/j.etap.2021.103650. View

4.
Masungi C, Mensch J, Van Dijck A, Borremans C, Willems B, Mackie C . Parallel artificial membrane permeability assay (PAMPA) combined with a 10-day multiscreen Caco-2 cell culture as a tool for assessing new drug candidates. Pharmazie. 2008; 63(3):194-9. View

5.
Shen H, Lai Y, Rodrigues A . Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. Drug Metab Dispos. 2016; 45(2):228-236. DOI: 10.1124/dmd.116.072264. View